Related Experiment Videos
New trends in paediatric antibiotic therapy.
1Paediatric Department IV, Sacco Hospital, Milan, Italy.
Drugs Under Experimental and Clinical Research
|January 1, 1987
Summary
New antibiotics offer limited advantages in pediatric care, with few exceptions like specific cephalosporins, aztreonam, and novel macrolides, which provide significant therapeutic improvements for certain infections.
Area of Science:
- Pediatric Infectious Diseases
- Pharmacology
- Microbiology
Background:
- Many new antibiotics for pediatric use lack advantages over older drugs and are expensive.
- Few novel antibiotics offer significant improvements in pediatric antibiotic therapy.
Purpose of the Study:
- To evaluate the therapeutic benefits of newly marketed antibiotics in pediatric patients.
- To identify specific antibiotics with unique characteristics for improved pediatric treatment.
Main Methods:
- Review of recently marketed antibiotics for pediatric use.
- Comparative analysis of efficacy, safety, and cost-effectiveness against older drugs.
- Focus on third-generation cephalosporins, aztreonam, and new macrolides.
Main Results:
- Ceftazidime and cefsulodin show high activity against Pseudomonas spp., aiding life-threatening infections.
- Aztreonam, a monobactam, targets aerobic Gram-negative bacilli with a safer profile than aminoglycosides.
- New macrolides are effective against erythromycin-resistant bacteria and have fewer side effects and drug interactions.
Conclusions:
- Specific new antibiotics like ceftazidime, cefsulodin, aztreonam, and new macrolides offer distinct advantages in pediatric care.
- Aztreonam presents a safer alternative for Gram-negative infections in children.
- New macrolides enhance compliance and efficacy, particularly for resistant Gram-positive strains.